Context Therapeutics Inc (CNTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $16.61M
Last updated: Nov 17, 2026 at 11:04 AM ET
Context Therapeutics Inc (CNTX) Earnings: Report Dates and Results
Context Therapeutics (CNTX) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Context Therapeutics reported EPS of -$0.08, above the -$0.09 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CNTX has an expected report date of Mar 22, 2027.
Earnings History
Of the 20 quarters below that had an estimate, CNTX beat 8, missed 9 and matched 3. The widest gap in the table came in the quarter ended Sep 30, 2024, when EPS landed 144.44% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.08 | -$0.09 | -$0.09 - -$0.07 | +11.11% | Beat | N/A | 8 | 3 up, 3 down | Nov 10, 2026 |
| Jun 30, 2026 | -$0.15 | -$0.10 | -$0.10 - -$0.07 | -50.00% | Miss | N/A | 8 | 6 up, 0 down | Aug 5, 2026 |
| Mar 31, 2026 | -$0.09 | -$0.12 | -$0.14 - -$0.06 | +25.00% | Beat | N/A | 8 | 6 up, 0 down | May 6, 2026 |
| Dec 31, 2025 | -$0.14 | -$0.10 | -$0.12 - -$0.07 | -36.59% | Miss | N/A | 9 | 1 up, 2 down | Mar 25, 2026 |
| Sep 30, 2025 | -$0.10 | -$0.09 | -$0.12 - -$0.03 | -11.11% | Miss | N/A | 4 | 1 up, 2 down | Nov 5, 2025 |
| Jun 30, 2025 | -$0.09 | -$0.05 | -$0.08 - -$0.01 | -80.00% | Miss | N/A | 5 | 0 up, 1 down | Aug 6, 2025 |
| Mar 31, 2025 | -$0.05 | -$0.06 | -$0.10 - -$0.04 | +16.67% | Beat | N/A | 3 | 1 up, 1 down | May 7, 2025 |
| Dec 31, 2024 | -$0.03 | -$0.06 | -$0.22 - -$0.04 | +47.09% | Beat | N/A | 5 | 1 up, 0 down | Mar 20, 2025 |
| Sep 30, 2024 | -$0.22 | -$0.09 | -$0.16 - -$0.05 | -144.44% | Miss | N/A | 2 | 0 up, 0 down | Nov 6, 2024 |
| Jun 30, 2024 | -$0.04 | -$0.07 | -$0.08 - -$0.07 | +42.86% | Beat | N/A | 2 | 0 up, 0 down | Aug 7, 2024 |
| Mar 31, 2024 | -$0.23 | -$0.44 | -$0.44 - -$0.44 | +47.73% | Beat | N/A | 1 | 1 up, 0 down | May 8, 2024 |
| Dec 31, 2023 | -$0.42 | -$0.35 | -$0.38 - -$0.32 | -20.00% | Miss | N/A | 2 | 0 up, 0 down | Mar 21, 2024 |
| Sep 30, 2023 | -$0.37 | -$0.31 | N/A | -19.35% | Miss | N/A | N/A | N/A | Nov 9, 2023 |
| Jun 30, 2023 | -$0.31 | -$0.20 | N/A | -55.00% | Miss | N/A | N/A | N/A | Aug 9, 2023 |
| Mar 31, 2023 | -$0.40 | -$0.19 | N/A | -110.53% | Miss | N/A | N/A | N/A | May 10, 2023 |
| Dec 31, 2022 | -$0.22 | -$0.22 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 22, 2023 |
| Sep 30, 2022 | -$0.24 | -$0.25 | N/A | +4.00% | Beat | N/A | N/A | N/A | Nov 9, 2022 |
| Jun 30, 2022 | -$0.25 | -$0.25 | N/A | 0.00% | In line | -125.8% | N/A | N/A | Aug 11, 2022 |
| Mar 31, 2022 | -$0.22 | -$0.24 | N/A | +8.33% | Beat | N/A | N/A | N/A | May 11, 2022 |
| Dec 31, 2021 | -$0.58 | -$0.58 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 24, 2022 |
| Sep 30, 2021 | -$0.46 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 2, 2021 |
| Jun 30, 2021 | $0.97 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 2, 2021 |
| Sep 30, 2018 | -$0.88 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 9, 2018 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.38, after -$0.52 the year before. It was -$0.95 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.38 | N/A |
| Dec 31, 2024 | -$0.52 | N/A |
| Dec 31, 2023 | -$1.50 | N/A |
| Dec 31, 2022 | -$0.93 | N/A |
| Dec 31, 2021 | -$0.95 | N/A |
Frequently Asked Questions About CNTX
When is Context Therapeutics's next earnings date?
Context Therapeutics's next earnings report is expected for Mar 22, 2027.
Did CNTX beat earnings estimates last quarter?
Yes. Context Therapeutics reported EPS of -$0.08 for the quarter ended Sep 30, 2026, above the -$0.09 estimate, a 11.11% surprise.
What EPS do analysts expect from CNTX next quarter?
The consensus EPS estimate for Context Therapeutics for the quarter ending Dec 31, 2026 is -$0.11 from 11 analysts, with estimates from -$0.17 to -$0.07.
How often does CNTX beat earnings estimates?
Context Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -9.73%.
CNTX pages: Overview, Earnings, Forecast, Financials, Competitors